Building upon these insights, a 2019 study by Goossens et al. further advanced the use of CRISPR technology by employing whole exome sequencing and CRISPR/Cas9 genome editing to repair a pathogenic SMCHD1 gene variant in patient-derived myoblasts, thereby providing a proof-of-concept for the feasibility of CRISPS/Cas9 as a targeted therapeutic strategy for FSHD [45]. The gene discussed is SMCHD1; the disease is facioscapulohumeral muscular dystrophy.